# 2025年11月18日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 叶酸修饰的姜源性外泌体样纳米颗粒共递送舒尼替尼通过抑制PI3K-Akt通路、下调P-糖蛋白及重编程巨噬细胞来抑制肾细胞癌

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243691](https://pubmed.ncbi.nlm.nih.gov/41243691)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243691
**DOI：** 10.1002/advs.202512563

### 第一部分 原文与翻译

**英文原标题：** Folic Acid-Modified Ginger-Derived Exosome-Like Nanoparticles Co-Delivering Sunitinib Suppress Renal Cell Carcinoma via PI3K-Akt Pathway Inhibition, P-gp Downregulation, and Macrophage Reprogramming.

**英文摘要原文：**
Renal cell carcinoma (RCC) is a malignant tumor with highly recurrent and metastatic capability. The current therapies for RCC are limited by drug resistance and toxic side effects. This study introduces an innovative approach that combines ginger-derived exosome-like nanoparticles (GELNs) with sunitinib (Su) and folic acid-polyethylene glycol (FA-PEG, FPD) in an active-passive targeting strategy to explore its multi-mechanism and synergistic therapeutic effects on RCC. GELNs are extracted via differential centrifugation combined with sucrose gradient ultracentrifugation. Metabolomics and network pharmacology predicted that GELNs may exert their anticancer efficacy via the PI3K-Akt signaling pathway, which is subsequently validated through in vitro experiments. By loading Su and modifying it with FPD, FPD-GELNs/Su is constructed. The FPD modification significantly enhanced tumor targeting and amplified the Su sensitivity by reducing ABCB1/P-gp expression induced by GELNs. In vivo experiments revealed that FPD-GELNs/Su promoted M1 macrophage polarization and increased immune T-cell infiltration by remodeling the tumor microenvironment, leading to significant inhibition of tumor growth and lung metastasis without causing notable liver or kidney toxicity. This study integrates network pharmacology with targeted delivery strategies, elucidating the mechanisms by which FPD-GELNs/Su inhibits RCC progression through multiple pathways, providing new insights for the development of precise and low-toxicity nano-therapies.

**中文摘要译文：**
肾细胞癌（RCC）是一种具有高度复发和转移能力的恶性肿瘤。目前针对RCC的治疗方法因耐药性和毒副作用而受到限制。本研究引入了一种创新方法，该方法在主被动靶向策略中将姜源性外泌体样纳米颗粒（GELNs）与舒尼替尼（Su）和叶酸-聚乙二醇（FA-PEG, FPD）相结合，旨在探索其对RCC的多机制协同治疗效果。GELNs通过差速离心结合蔗糖梯度超速离心法进行提取。代谢组学和网络药理学预测，GELNs可能通过PI3K-Akt信号通路发挥其抗癌功效，这随后通过体外实验得到了验证。通过负载Su并用FPD进行修饰，构建了FPD-GELNs/Su。FPD修饰通过降低由GELNs诱导的ABCB1/P-gp表达，显著增强了肿瘤靶向性并放大了Su的敏感性。体内实验表明，FPD-GELNs/Su通过重塑肿瘤微环境，促进了M1型巨噬细胞极化并增加了免疫T细胞浸润，从而显著抑制了肿瘤生长和肺转移，且未引起明显的肝肾毒性。本研究将网络药理学与靶向递送策略相结合，阐明了FPD-GELNs/Su通过多通路抑制RCC进展的机制，为开发精准、低毒的纳米疗法提供了新见解。

### 第二部分 AI 大师评价

本研究巧妙地构建了一种基于姜源性外泌体样纳米颗粒的新型药物递送系统，用于靶向治疗肾细胞癌。该系统通过共递送化疗药物舒尼替尼并进行叶酸修饰，实现了对肿瘤细胞的主动和被动双重靶向。其核心创新点在于，该纳米药物不仅通过抑制PI3K-Akt通路直接杀伤肿瘤，还能下调P-gp蛋白表达以逆转耐药性，并重塑肿瘤微环境、激活抗肿瘤免疫。这项研究为开发低毒、高效的天然纳米药物提供了新思路，在克服肾癌耐药和转移方面展现出巨大的临床转化潜力。

---

## 2. 靶向高血糖诱导的转移前微环境以预防乳腺癌骨转移：机制与治疗策略

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243293](https://pubmed.ncbi.nlm.nih.gov/41243293)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243293
**DOI：** 10.1002/advs.202519858

### 第一部分 原文与翻译

**英文原标题：** Targeting the Hyperglycemic Pre-Metastatic Niche to Prevent Breast Cancer Bone Metastasis: Mechanisms and Therapeutic Strategies.

**英文摘要原文：**
The recent pioneering study by Ye et al. (Adv Sci. 2025;12(37):e0504924) provides compelling evidence that systemic hyperglycemia orchestrates a pre-metastatic niche (PMN) in bone, promoting breast cancer metastasis and identifying Receptor for Advanced Glycation End-products (RAGE) inhibition as a viable therapeutic strategy. While this work represents a significant conceptual advance by linking systemic metabolism to organotropic metastasis, the analysis identifies several substantive challenges that must be addressed to translate this finding into clinical practice. First, the authors clarify that the primary driver of enhanced bone metabolism is likely tumor-derived educative signals, with hyperglycemia acting as a secondary sensitizer rather than a sole instigator; this hierarchical causality requires further dissection. Second, the pleiotropic roles of RAGE in physiology and immunity raise concerns about the potential for on-target, adverse effects with long-term inhibition, necessitating the development of more targeted approaches. Finally, while the primary metabolic therapy proposed is GP-mediated glucose deprivation, the therapeutic efficacy demonstrated in a preventative model requires validation in scenarios of established micro-metastases, which mirror the clinical reality more closely. This critical appraisal underscores the need for a more nuanced understanding of the niche's biology and a rigorous evaluation of the proposed therapeutic paradigm's safety and timing.

**中文摘要译文：**
Ye等人最近的开创性研究（Adv Sci. 2025;12(37):e0504924）提供了有力证据，表明全身性高血糖在骨中构建了一个转移前微环境（PMN），从而促进乳腺癌的转移，并指出抑制晚期糖基化终末产物受体（RAGE）是一种可行的治疗策略。尽管这项工作通过将全身性代谢与器官趋向性转移联系起来，代表了一项重大的概念性进展，但分析也指出了将此发现转化为临床实践前必须解决的几个实质性挑战。首先，作者阐明，促进骨代谢增强的主要驱动因素可能是肿瘤来源的教育性信号，而高血糖则扮演着次要的敏化剂角色，而非唯一的始动因素；这种层级因果关系有待进一步剖析。其次，RAGE在生理和免疫中扮演的多效性角色，引发了人们对其长期抑制可能带来的在靶不良反应的担忧，这使得开发更具靶向性的方法成为必要。最后，虽然所提出的主要代谢疗法是GP介导的葡萄糖剥夺，但其在预防模型中展示的疗效，仍需在已形成微转移灶的场景下进行验证，因为后者更贴近临床实际情况。这项批判性评估强调，我们需要对该微环境的生物学有更精细的理解，并对所提出的治疗范式的安全性与时机进行严格的评估。

### 第二部分 AI 大师评价

本文是对一项开创性研究的批判性评述，该研究揭示了全身性高血糖通过构建骨内“转移前微环境”来促进乳腺癌骨转移。文章在肯定其将系统性代谢与器官特异性转移联系起来的创新性概念价值的同时，也深刻指出了其临床转化面临的挑战。评价重点分析了肿瘤信号与高血糖的主次关系、长期抑制RAGE可能引发的不良反应，以及在已形成微转移灶的临床相关模型中验证疗效的必要性，为该领域的后续研究指明了审慎的方向。

---

## 3. 人工智能引导的表面增强拉曼光谱技术确定了一种泛癌种诊断生物标志物

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243246](https://pubmed.ncbi.nlm.nih.gov/41243246)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243246
**DOI：** 10.1002/advs.202516268

### 第一部分 原文与翻译

**英文原标题：** AI-Guided SERS Defines a Pan-Cancer Diagnostic Biomarker.

**英文摘要原文：**
Early and accurate detection of multiple cancers through a single test remains an unmet clinical need, hindered by current limitations in accuracy, throughput, automation, and multiplexing. Here, we present an AI-powered SERS chip that combines automated exosome capture with AI-enabled molecular fingerprinting to accurately distinguish ten common cancer types from a single serum test. The system employs a peptide-functionalized SERS chip enabling the selective enrichment of exosomes directly from patient serum, enhancing label-free Raman fingerprint signals. AI-driven spectral analysis achieved 97.4% accuracy in distinguishing cancer from healthy samples, 97.08% accuracy for early-stage cancer detection, and 93.89% accuracy in classifying ten common cancer types, including breast, thyroid, esophageal, kidney, pancreatic, duodenal, lung, colorectal, ovarian, and gastric cancers. Crucially, based on molecular profiling, we identified exosomal deoxyadenosine triphosphate as a promising pan-cancer biomarker consistently upregulated across diverse tumor types. This discovery establishes a potential pan-cancer diagnostic marker, while the fully automated, scalable platform offers significant promise for clinical translation in early and differential cancer diagnosis.

**中文摘要译文：**
通过单次检测实现多种癌症的早期精准筛查仍是一个未被满足的临床需求，其发展受限于当前技术在准确性、通量、自动化和多重检测能力方面的局限。本研究中，我们展示了一种由人工智能驱动的SERS芯片，该芯片结合了自动化的外泌体捕获技术与人工智能赋能的分子指纹图谱分析，能够通过单次血清检测准确区分十种常见癌症类型。该系统采用了一种肽功能化的SERS芯片，能够直接从患者血清中选择性富集外泌体，从而增强无标记的拉曼指纹信号。人工智能驱动的光谱分析在区分癌症样本与健康样本方面实现了97.4%的准确率，在早期癌症检测方面达到97.08%的准确率，并在对包括乳腺癌、甲状腺癌、食管癌、肾癌、胰腺癌、十二指肠癌、肺癌、结直肠癌、卵巢癌和胃癌在内的十种常见癌症进行分类时，准确率达到93.89%。至关重要的是，基于分子谱分析，我们确定了外泌体中的脱氧三磷酸腺苷是一种极具潜力的泛癌种生物标志物，其在多种不同类型的肿瘤中均表现出一致的上调。这一发现确立了一种潜在的泛癌种诊断标志物，同时，该全自动、可扩展的平台为实现其在癌症早期诊断和鉴别诊断中的临床转化提供了巨大的应用前景。

### 第二部分 AI 大师评价

本研究旨在解决单次检测实现多种癌症早期精准筛查的临床难题。研究团队创新性地开发了一种结合人工智能（AI）与表面增强拉曼光谱（SERS）技术的芯片平台，通过自动捕获血清外泌体并分析其分子指纹，实现了对十种常见癌症的高精度区分。其核心亮点在于不仅验证了该技术平台在泛癌种及早期癌症检测中的高准确率，更重要的是发现并确定了外泌体中的脱氧三磷酸腺苷（dATP）可作为一种潜力巨大的新型泛癌种诊断生物标志物。这项工作为开发全自动、高通量的癌症液体活检新范式提供了坚实基础，具有重大的临床转化潜力。

---

## 4. 靶向CD169+巨噬细胞的免疫调节剂：恢复吞噬功能并增强抗原呈递以根除淋巴转移

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243224](https://pubmed.ncbi.nlm.nih.gov/41243224)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243224
**DOI：** 10.1002/advs.202514386

### 第一部分 原文与翻译

**英文原标题：** CD169 Macrophage-Targeted Immunomodulator to Restore Phagocytic Function and Enhance Antigen Presentation for Lymphatic Metastasis Eradication.

**英文摘要原文：**
Lymphatic metastasis is a major cause of tumor treatment failure, with the immunosuppressive status of lymphatic macrophages significantly impairing antitumor immunity. In this study, it is found that CD169 macrophages in lymphatic metastasis exhibit impaired phagocytic activity and diminished antigen-presenting capacity, which correlates with suppressed antitumor immune responses. Based on these discoveries, a CD169 macrophage-targeted immunomodulator (designated as G-LNP@S-D) is fabricated to restore phagocytic function and enhance antigen presentation for lymphatic metastasis eradication. G-LNP@S-D consists of GM1-functionalized liposomes co-encapsulating the SHP2 inhibitor SHP099 and the STING agonist DMXAA, enabling sequential lymph node- and CD169 macrophage-specific drug delivery. Mechanistically, G-LNP@S-D not only restores the phagocytic capacity of CD169 macrophages to eliminate tumor cells but also activates the STING pathway to enhance antigen presentation and subsequent T cell priming. Immunological profiling confirms that G-LNP@S-D treatment promotes the infiltration of CD4 and CD8 T cells in both TDLNs and primary tumors. Importantly, G-LNP@S-D exerts systemic immunomodulatory effects for directly eradicating lymphatic metastases. This study elucidates a sophisticated lymph node immune-modulation strategy and provides a promising therapeutic approach to treat lymphatic metastasis.

**中文摘要译文：**
淋巴转移是肿瘤治疗失败的主要原因，而淋巴巨噬细胞的免疫抑制状态显著削弱了抗肿瘤免疫。本研究发现，淋巴转移中的CD169+巨噬细胞表现出吞噬活性受损和抗原呈递能力下降，这与抗肿瘤免疫反应受到抑制相关。基于这些发现，本研究构建了一种靶向CD169+巨噬细胞的免疫调节剂（命名为G-LNP@S-D），旨在恢复其吞噬功能并增强抗原呈递，从而根除淋巴转移。G-LNP@S-D由GM1功能化的脂质体组成，该脂质体共包裹了SHP2抑制剂SHP099和STING激动剂DMXAA，从而实现了序贯性的淋巴结及CD169+巨噬细胞特异性药物递送。从机制上讲，G-LNP@S-D不仅恢复了CD169+巨噬细胞吞噬并清除肿瘤细胞的能力，还激活了STING通路以增强抗原呈递及后续的T细胞启动。免疫学分析证实，G-LNP@S-D治疗促进了CD4+和CD8+ T细胞在肿瘤引流淋巴结和原发肿瘤中的浸润。重要的是，G-LNP@S-D能发挥全身性免疫调节作用，从而直接根除淋巴转移灶。这项研究阐明了一种精密的淋巴结免疫调节策略，并为治疗淋巴转移提供了一种有前景的治疗方法。

### 第二部分 AI 大师评价

本研究针对淋巴转移中CD169+巨噬细胞功能受损这一关键免疫抑制问题，设计了一种靶向递送的纳米免疫调节剂（G-LNP@S-D）。该药物通过共递送SHP2抑制剂和STING激动剂，成功地“一石二鸟”——既恢复了巨噬细胞的吞噬能力，又增强了其抗原呈递功能，从而有效激活了抗肿瘤T细胞免疫。这项工作不仅揭示了重塑淋巴结免疫微环境以治疗转移瘤的精妙策略，其设计的靶向纳米平台也为开发针对特定免疫细胞群的癌症免疫疗法提供了极具价值的范例。

---

## 5. 可注射、原位水化增强型复合骨水泥用于加速骨再生

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243223](https://pubmed.ncbi.nlm.nih.gov/41243223)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243223
**DOI：** 10.1002/advs.202512723

### 第一部分 原文与翻译

**英文原标题：** Injectable and In Situ Hydration-Reinforced Hybrid Bone Cements for Accelerated Bone Regeneration.

**英文摘要原文：**
Injectable bone cements are recognized as ideal solution for bone augmentation due to their minimally invasive introduction strategy. However, current clinical formulations and composites, while demonstrating improvements in certain areas, often fail to comprehensively address challenges, including rheological injectability, mechanical stability, interconnected porosity, degradability, and bioactivity. To overcome limitations, a novel bone cement comprising linear polyhydroxy PEGylated poly(glycerol sebacate) (L-PEGS) and calcium phosphate cement (CPC) is developed. The incorporation of L-PEGS enhances injectability and reinforces the mechanical weakness of CPC, resulting in improvement in compressive strength (increased by 16.7 folds) and fatigue resistance (1000 cycles). Owing to linear polyhydroxy backbone, L-PEGS initiates self-reinforcing cross-linking reaction synchronized with the hydration of CPC into hydroxyapatite. This hydration reinforcement is mediated by its abundant hydroxyl groups and high water absorption capacity, which accelerate hydration kinetics. Concurrently, the cross-linking reaction generates in situ carbon dioxide, resulting in porous microarchitecture that facilitates hydration process, enhances cement degradability, and promotes nutrient exchange and new bone ingrowth. In vitro and vivo studies confirmed that L-PEGS/CPC substantially enhances osteogenesis compared to clinical materials. Collectively, this injectable, hydration-driven, and self-reinforcing bone cement offers comprehensive solution to the challenges in current bone graft materials, holding promise for clinical bone repair.

**中文摘要译文：**
由于其微创植入的特点，可注射骨水泥被认为是骨增量的理想解决方案。然而，目前的临床配方和复合材料虽然在某些方面有所改进，但通常无法全面解决包括流变可注射性、机械稳定性、互连孔隙结构、可降解性和生物活性在内的诸多挑战。为克服这些局限性，本研究开发了一种由线性多羟基聚乙二醇化聚（癸二酸甘油酯）（L-PEGS）和磷酸钙骨水泥（CPC）组成的新型骨水泥。L-PEGS的加入增强了CPC的可注射性并弥补了其机械性能的不足，使其抗压强度提高了16.7倍，并增强了其抗疲劳性（1000次循环）。由于其线性多羟基骨架，L-PEGS能引发自增强交联反应，该反应与CPC水化形成羟基磷灰石的过程同步进行。这种水化增强作用是通过其丰富的羟基和高吸水能力介导的，从而加速了水化动力学。同时，交联反应会原位产生二氧化碳，形成多孔微结构，这不仅促进了水化过程、提高了骨水泥的可降解性，还有利于营养交换和新骨长入。体外和体内研究证实，与临床现有材料相比，L-PEGS/CPC能显著增强成骨作用。总而言之，这种可注射、水化驱动的自增强型骨水泥为当前骨移植材料所面临的挑战提供了全面的解决方案，为临床骨修复带来了希望。

### 第二部分 AI 大师评价

本研究旨在开发一种新型复合骨水泥以克服现有临床材料在力学性能、可注射性及生物活性等方面的综合挑战。研究人员巧妙地将一种新型线性多羟基聚合物（L-PEGS）与磷酸钙骨水泥（CPC）相结合，发现该复合材料不仅大幅提升了抗压强度和抗疲劳性，还能通过与水化同步的自增强交联反应原位产生多孔结构。这一设计极具创新性，通过单一组分同时解决了力学增强、促进降解和引导新骨长入等多个关键问题，为开发下一代高性能骨修复材料提供了极具前景的新策略。

---

## 6. 乳酸化SPTAN1通过促进NOTCH1/HES1激活与免疫抑制加速肝细胞癌进展。

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/41243220](https://pubmed.ncbi.nlm.nih.gov/41243220)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41243220
**DOI：** 10.1002/advs.202507068

### 第一部分 原文与翻译

**英文原标题：** Lactylated SPTAN1 Accelerates Hepatocellular Carcinoma Progression by Promoting NOTCH1/HES1 Activation and Immunosuppression.

**英文摘要原文：**
Nonerythrocytic alphaII-spectrin (SPTAN1) is crucial for neuronal functions, yet its role in oncogenic processes remains inadequately characterized. This study investigates the lactylation (kla) modification of SPTAN1 (SPTAN1-kla) and its mechanistic contributions to hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Results indicate that SPTAN1 undergoes lactylation at lysine residues K1952 and K1957 specifically in HBV-positive HCC tissues. Alanyl-tRNA synthetase 1 (AARS1) mediates SPTAN1-kla formation, while histone deacetylase 1 (HDAC1) acts as a delactylase. HBV infection enhances lactate production by inducing the expression of HK2, promoting SPTAN1-kla formation, and disrupting the liquid-liquid phase separation (LLPS) of cytoplasmic SPTAN1, thereby facilitating its nuclear translocation. Within the nucleus, SPTAN1-kla interacts with core-binding factor β (CBFB) to activate NOTCH1/HES1 signaling, thereby promoting HCC cell proliferation. Furthermore, SPTAN1-kla activates the COX2/mPGES1 pathway through NOTCH1/HES1 signaling, thereby enhancing the biosynthesis of prostaglandin E2 (PGE2) and increasing the infiltration of exhausted CD8⁺ T cells. Therapeutic targeting of SPTAN1-kla using specific inhibitory peptides significantly attenuates HCC tumor growth in preclinical models. Our research identifies SPTAN1-kla as a novel oncogenic driver in HBV-related HCC, functioning via metabolic reprogramming and immune modulation. These findings position SPTAN1-kla as a promising therapeutic target for developing precision interventions against HBV-related HCC.

**中文摘要译文：**
非红细胞αII-血影蛋白 (SPTAN1) 对神经元功能至关重要，但其在肿瘤发生过程中的作用尚未得到充分阐明。本研究旨在探讨SPTAN1的乳酸化 (kla) 修饰 (SPTAN1-kla) 及其在乙型肝炎病毒 (HBV) 相关肝细胞癌 (HCC) 中的作用机制。结果表明，SPTAN1在HBV阳性的HCC组织中，其赖氨酸残基K1952和K1957位点会发生特异性乳酸化。丙氨酰-tRNA合成酶1 (AARS1) 介导SPTAN1-kla的形成，而组蛋白去乙酰化酶1 (HDAC1) 则作为其去乳酸化酶。HBV感染通过诱导HK2的表达来增加乳酸生成，从而促进SPTAN1-kla的形成，并破坏细胞质中SPTAN1的液-液相分离 (LLPS) 过程，进而促使其核转位。在细胞核内，SPTAN1-kla与核心结合因子β (CBFB) 相互作用，激活NOTCH1/HES1信号通路，从而促进HCC细胞的增殖。此外，SPTAN1-kla还通过NOTCH1/HES1信号通路激活COX2/mPGES1通路，进而增强前列腺素E2 (PGE2) 的生物合成，并增加耗竭性CD8⁺ T细胞的浸润。在临床前模型中，使用特异性抑制肽靶向SPTAN1-kla能显著减缓HCC肿瘤的生长。我们的研究将SPTAN1-kla鉴定为HBV相关HCC中一个新的致癌驱动因子，其通过代谢重编程和免疫调节发挥作用。这些发现将SPTAN1-kla定位为一个有前景的治疗靶点，为开发针对HBV相关HCC的精准干预措施提供了新方向。

### 第二部分 AI 大师评价

本研究聚焦于乙肝病毒相关肝癌（HBV-HCC）的病理机制，创新性地揭示了非红细胞αII-血影蛋白（SPTAN1）的乳酸化修饰在其中的关键驱动作用。研究通过一系列分子和细胞生物学实验，清晰地阐明了SPTAN1乳酸化如何通过激活NOTCH1/HES1信号通路，一方面促进肿瘤细胞增殖，另一方面诱导免疫抑制微环境的形成。这项发现不仅深化了我们对HBV-HCC代谢重编程与免疫逃逸关联的理解，更重要的是，它将SPTAN1乳酸化鉴定为一个极具潜力的新型诊断标志物和精准治疗靶点。

---

## 7. GLP-1受体激动剂的心血管效应与耐受性：一项涉及99,599名患者的系统综述与荟萃分析

**原文链接：** [https://pubmed.ncbi.nlm.nih.gov/40892610](https://pubmed.ncbi.nlm.nih.gov/40892610)
**期刊：** Journal of the American College of Cardiology
**PMID：** 40892610
**DOI：** 10.1016/j.jacc.2025.08.027

### 第一部分 原文与翻译

**英文原标题：** Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients.

**英文摘要原文：**
BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant cardiovascular (CV) benefits, particularly in patients with diabetes mellitus, but the safety and efficacy of different GLP-1 RAs across diverse populations remain insufficiently defined.

OBJECTIVES: Previous meta-analyses of GLP-1 RAs have been limited by restricted populations, omission of recent trials, or incomplete safety synthesis; this study integrates the latest evidence across 21 randomized controlled trials and diverse populations using advanced meta-analytic methods.

METHODS: Randomized controlled trials comparing GLP-1 RAs vs controls or placebo were included. Analyses were conducted in prespecified subgroups based on the GLP-1 RA used. Prespecified subgroups according to diabetes mellitus, kidney function, obesity, or heart failure were also performed. Main outcomes comprised mortality (all-cause and CV), trial-defined major adverse cardiovascular events (MACE) and serious adverse events. GRADE (Grading of Recommendations Assessment, Development and Evaluation) and trial sequential analyses were performed to evaluate certainty and conclusiveness of findings, respectively.

RESULTS: A total of 21 trials encompassing 99,599 patients were included. Eight different GLP-1 RAs were used (lixisenatide, liraglutide, exenatide, semaglutide, efpeglenatide, dulaglutide, albiglutide, and tirzepatide), each administered at therapeutic doses and compared vs placebo or controls. Mean follow-up duration was 2.4 years. We found conclusive, high-certainty evidence that GLP-1 RAs reduced all-cause death (incidence rate ratio [IRR]: 0.88; 95% CI: 0.84-0.92; needed to treat [NNT] = 121), CV death (IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170), and MACE (IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66), compared with controls. GLP-1 RAs reduced serious adverse events (-9%), myocardial infarction (-15%), acute kidney failure (-9%), heart failure (-15%), and infections (-10%), but increased gastrointestinal (+63%) and gallbladder (+26%) disorders. There were no differences in stroke, pancreatitis, or neoplasm between groups. Results were mostly consistent across subgroups. Analysis by GLP-1 RA type revealed potential differences in efficacy and safety profiles.

CONCLUSIONS: GLP-1 RAs reduce mortality and MACE in high-risk populations, highlighting benefits beyond glycemic control. These come at an increased risk of gastrointestinal and gallbladder risks. Variation in efficacy and tolerability supports tailoring GLP-1 RA therapy to individual patient characteristics and treatment goals. (PROSPERO [GLP-1 RAs Reduce Mortality and Cardiovascular Events Across the Spectrum of Treated Patients: A Systematic Review and Meta-Analysis]; CRD420251032222).

**中文摘要译文：**
背景：胰高血糖素样肽-1受体激动剂（GLP-1 RAs）已显示出显著的心血管（CV）益处，尤其是在糖尿病患者中，但不同GLP-1 RAs在多样化人群中的安全性与有效性仍有待充分明确。

目的：以往关于GLP-1 RAs的荟萃分析受限于特定人群、遗漏了近期试验或安全性综合分析不完整；本研究采用先进的荟萃分析方法，整合了涵盖21项随机对照试验和多样化人群的最新证据。

方法：本研究纳入了比较GLP-1 RAs与对照组或安慰剂的随机对照试验。根据所使用的GLP-1 RA类型进行了预设亚组分析，同时还根据糖尿病、肾功能、肥胖或心力衰竭状况进行了预设亚组分析。主要结局包括死亡率（全因和心血管）、试验定义的主要不良心血管事件（MACE）以及严重不良事件。采用GRADE（推荐、评估、发展和评价分级）和试验序贯分析法分别评估研究结果的证据确定性和结论性。

结果：共纳入21项试验，涵盖99,599名患者。试验中使用了八种不同的GLP-1 RAs（利西拉来、利拉鲁肽、艾塞那肽、司美格鲁肽、efpeglenatide、度拉糖肽、阿必鲁肽和替西帕肽），均以治疗剂量给药，并与安慰剂或对照组进行比较。平均随访时间为2.4年。我们发现了确凿的、高确定性的证据表明，与对照组相比，GLP-1 RAs降低了全因死亡率（发生率比[IRR]: 0.88; 95% CI: 0.84-0.92; 需治疗人数[NNT] = 121）、心血管死亡率（IRR: 0.87; 95% CI: 0.81-0.92; NNT = 170）和MACE（IRR: 0.87; 95% CI: 0.83-0.91; NNT = 66）。GLP-1 RAs降低了严重不良事件（-9%）、心肌梗死（-15%）、急性肾衰竭（-9%）、心力衰竭（-15%）和感染（-10%），但增加了胃肠道（+63%）和胆囊（+26%）疾病的风险。两组在卒中、胰腺炎或肿瘤方面的发生率无差异。结果在各亚组中基本保持一致。按GLP-1 RA类型进行的分析揭示了不同药物在有效性和安全性方面可能存在差异。

结论：GLP-1 RAs能降低高危人群的死亡率和MACE，凸显了其超越血糖控制的益处。然而，这些益处伴随着胃肠道和胆囊疾病风险的增加。不同药物在疗效和耐受性上的差异，支持根据患者个体特征和治疗目标来定制GLP-1 RA治疗方案。（PROSPERO [GLP-1 RAs在各类治疗患者中降低死亡率和心血管事件：一项系统综述与荟萃分析]；CRD420251032222）。

### 第二部分 AI 大师评价

该研究是一项大规模、高质量的系统综述与荟萃分析，通过整合近十万名患者的数据，全面评估了GLP-1受体激动剂的心血管保护效应与安全性。其创新之处在于纳入了最新的临床试验和多样化的人群亚组，并采用先进的分析方法，为GLP-1 RAs能显著降低全因死亡率、心血管死亡和主要不良心血管事件提供了高确定性的证据。研究不仅明确了其超越降糖的广泛心血管及肾脏益处，也客观指出了胃肠道和胆囊相关风险的增加。这项研究的结论极具临床指导价值，它有力地支持了在高风险人群中广泛应用此类药物，并强调了根据不同药物的效能与安全性特征进行个体化治疗决策的重要性。

---

速递结束，祝您工作愉快！